Biogen gains ophthalmology biosimilar candidates for Lucentis, Eylea in deal with Samsung Bioepis
Samsung Biologics Prepares for Budding Alzheimer's Treatment Deals
Logo De Société De Biotechnologie De Biogen Image éditorial - Image du médecines, hématologique: 102563960
Biogen of US might reap W2tr from Samsung Bioepis call option
Samsung Bioepis ponders acquiring unit from U.S. partner Biogen
Samsung Bioepis looks to acquire Biogen's biosim unit: reports
Samsung Bioepis conclut un nouvel accord de commercialisation avec Biogen
Biogen/Samsung Takeover - Deal Or No Deal?
Samsung Bioepis considering takeover of Biogen's unit: reports
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung intéressé par le rachat du laboratoire Biogen pour plus de $40 milliards | Arab News FR
Samsung intéressé par le rachat du laboratoire Biogen | La Presse
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake | BioSpace
Biogen — Wikipédia
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache | Fierce Pharma
Samsung BioLogics says report on Biogen deal talks untrue | Fox Business
Biogen Poised for Pipeline Growth, Samsung Eyes New Drug Expansion after $2.3B Joint Venture Deal
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million | BioSpace
Samsung Bioepis seeks to buy Biogen biosimilar unit - KED Global
Is Samsung really 'at negotiating table' for Biogen? What we know so far - MM+M
Biogen shares jump higher on report of potential Samsung acquisition
Samsung in talks to acquire Biogen, per report - The Boston Globe
Samsung Biologics Buys Bioepis Stake for $2.3 Billion From Biogen - Bloomberg
Samsung Group reportedly in talks to acquire Biogen < Pharma < Article - KBR
Samsung Biologics to acquire Biogen's stake in Samsung Bioepis
